Identification of receptors and enzymes for endocannabinoids in NSC-34 cells: Relevance for in vitro studies with cannabinoids in motor neuron diseases

Neuroscience Letters

Volumn 508, Issue 2, 2012, Pages 67-72

  Moreno Martet, Miguel ^a,b,c   Mestre, Leyre ^d   Loría, Frida ^d   Guaza, Carmen ^d   Fernández Ruiz, Javier ^a,b,c   De Lago, Eva ^a,b,c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^d INSTITUTO CAJAL   (Spain)

Author keywords

Cannabinoid signaling system; Cannabinoids; CB1 and CB2 receptors; Endocannabinoid enzymes; Motor neuron disease; NSC 34 cells

Indexed keywords

ACYLGLYCEROL LIPASE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; GLUTAMATE RECEPTOR; LIPOPROTEIN LIPASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CELL SURVIVAL; ENZYME SYNTHESIS; EXCITOTOXICITY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOTOR NEURON DISEASE; MOUSE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

AMIDOHYDROLASES; ANIMALS; ENDOCANNABINOIDS; GENE EXPRESSION; HYBRIDOMAS; LIPOPROTEIN LIPASE; MICE; MONOACYLGLYCEROL LIPASES; MOTOR NEURON DISEASE; MOTOR NEURONS; PHOSPHOLIPASE D; RECEPTOR, CANNABINOID, CB1;

EID: 84856079421     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.12.020     Document Type: Article

References (25)

1. Barber S.C., Higginbottom A., Mead R.J., Barber S., Shaw P.J. An in vitro screening cascade to identify neuroprotective antioxidants in ALS. Free Radic. Biol. Med. 2009, 46:1127-1138.
2. Bilsland L.G., Dick J.R., Pryce G., Petrosino S., Di Marzo V., Baker D., Greensmith L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J. 2006, 20:1003-1005.
3. Bilsland L.G., Greensmith L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr. Pharm. Des. 2008, 14:2306-2316.
4. Bruijn L.I., Miller T.M., Cleveland D.W. Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 2004, 27:723-749.
5. Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma×spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992, 194:209-221.
6. Durham H.D., Dahrouge S., Cashman N.R. Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology 1993, 14:387-395.
7. Eggett C.J., Crosier S., Manning P., Cookson M.R., Menzies F.M., McNeil C.J., Shaw P.J. Development and characterisation of a glutamate-sensitive motor neurone cell line. J. Neurochem. 2000, 74:1895-1902.
8. Fernández-Ruiz J., García C., Sagredo O., Gómez-Ruiz M., de Lago E. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin. Ther. Targets 2010, 14:387-404.
9. Foran E., Trotti D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox Signal. 2009, 11:1587-1602.
10. Guo G., Bhatt N.R. p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem. Res. 2007, 32:2160-2166.
11. Habib A.A., Mitsumoto H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin. Emerg. Drugs 2011, 16:537-558.
12. Kim K., Moore D.H., Makriyannis A., Abood M.E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol. 2006, 542:100-105.
13. Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010, 9:995-1007.
14. Raman C., McAllister S.D., Rizvi G., Patel S.G., Moore D.H., Abood M.E. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004, 5:33-39.
15. Rodríguez M., Zoecklein L.J., Howe C.L., Pavelko K.D., Gamez J.D., Nakane S., Papke L.M. Gamma interferon is critical for neuronal viral clearance and protection in a susceptible mouse strain following early intracranial Theiler's murine encephalomyelitis virus infection. J. Virol. 2003, 77:12252-12265.
16. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., Brown R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
17. Sargsyan S.A., Monk P.N., Shaw P.J. Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis. Glia 2005, 51:241-253.
18. Shoemaker J.L., Seely K.A., Reed R.L., Crow J.P., Prather P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem. 2007, 101:87-98.
19. Strong M., Rosenfeld J. Amyotrophic lateral sclerosis: a review of current concepts. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2003, 4:136-143.
20. Tabata R.C., Wilson J.M., Ly P., Zwiegers P., Kwok D., Van Kampen J.M., Cashman N., Shaw C.A. Chronic exposure to dietary sterol glucosides is neurotoxic to motor neurons and induces an ALS-PDC phenotype. Neuromol. Med. 2008, 10:24-39.
21. Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004, 15:601-609.
22. Weydt P., Hong S., Witting A., Möller T., Stella N., Kliot M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2005, 6:182-184.
23. Witting A., Weydt P., Hong S., Kliot M., Möller T., Stella N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem. 2004, 89:1555-1557.
24. Xu R., Tao Y., Wu C., Yi J., Yang Y., Yang R., Hong D. Domoic acid induced spinal cord lesions in adult mice: evidence for the possible molecular pathways of excitatory amino acids in spinal cord lesions. Neurotoxicology 2008, 29:700-707.
25. Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., Banati R.R., Anand P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 2006, 6:12.